Physician profile
Jean E Keamy
NPI 1144250564
$2,446.91
in general payments reported to CMS, 2019-2025
11 companies · $226 in 2025
The $226 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2020: $106 · 2021: $208 · 2022: $827 · 2023: $163 · 2024: $68.95 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $457.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beaver-Visitec International, INC. | $650.00 | 2022 | |
| Alcon Vision LLC | $502.39 | 2019-2024 | Argos |
| Merz North America, INC. | $376.01 | 2019 | |
| Galderma Laboratories, L.P. | $329.29 | 2019-2021 | |
| Glaukos Corporation | $233.14 | 2020-2025 | Idosetr |
| Abbvie INC. | $113.44 | 2022-2024 | |
| Oyster Point Pharma, INC. | $78.31 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $73.57 | 2023 | Lipiflow System Activator II (Disposable, Visine For Contacts |
| Allergan, INC. | $36.67 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $28.70 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $25.39 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Keamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.